# An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

> **NCT03911869** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** encorafenib
- **DRUG:** binimetinib

## Key facts

- **NCT ID:** NCT03911869
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-30
- **Primary completion:** 2022-01-27
- **Final completion:** 2022-01-27
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study terminated due to lack of enrollment of the target population. There were no safety, efficacy, or regulatory interaction involved in the decision to stop enrollment.
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911869, "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03911869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*